SCHEMBL25433735

SCHEMBL25433735

COc1ccc(-c2noc(C3CNC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
TP53 P04637 1/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
ALDH1A1 P00352 4/20 0.54
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
S1PR1 P21453 1/20 0.51
NR1H4 Q96RI1 1/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
HSD17B10 Q99714 1/20 0.51
GAA P10253 2/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
POLB P06746 2/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193523 0.87 ALDH1A1 (0.54) MAPTTP53SMN1; SMN2ALDH1A1NPC1
SCHEMBL4425801 0.86 NR1H4 (0.64) MAPTTP53SMN1; SMN2ALDH1A1NPC1
Hydrochloric Acid SCHEMBL412823 0.86 ALDH1A1 (0.53) MAPTTP53SMN1; SMN2ALDH1A1NPC1
SCHEMBL22280438 0.84 NPC1 (0.68) MAPTNPC1RAB9ANR1H4MEN1
SCHEMBL30584793 0.77 ALDH1A1 (0.56) MAPTTP53SMN1; SMN2ALDH1A1NPSR1
SCHEMBL22280306 0.76 S1PR1 (0.53) NPSR1S1PR1NR1H4MEN1KMT2A
SCHEMBL20676389 0.76 ALDH1A1 (0.55) MAPTTP53SMN1; SMN2ALDH1A1NPC1
SCHEMBL30584896 0.76 ALDH1A1 (0.58) MAPTTP53SMN1; SMN2ALDH1A1NPSR1
Hydrochloric Acid SCHEMBL22265604 0.75 L3MBTL1 (0.47) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL25172097 0.75 ALDH1A1 (0.62) MAPTSMN1; SMN2ALDH1A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 MAPT 2999/4885TP53 54/4885SMN1; SMN2 3115/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MAPT 2999/4885TP53 54/4885SMN1; SMN2 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.